Sanofi's valuations are attractive: Why it is stock pick of week
Synopsis
Sanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push, recent underperformance and the resultant lower valuation are the other factors that have made the company a favourite of analysts.
Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its
